$IMTX positive clinical data update from Phase 1 trials

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation

·Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products

·Treatment-emergent adverse events were transient and manageable

finance.yahoo.com/news/immatics-presents-data-dose-escalation-110000980.html